IP Library Granted Patent US 9,657,294
Granted Patent B2
US 9,657,294 · App. 14/861,805 · Granted May 23, 2017

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

Inventors: Leonid Beigelman (San Mateo, CA); James McSwiggen (Arlington, MA); Chandra Vargeese (Schwenksville, PA)
Assignee: SIRNA THERAPEUTICS, INC.
C12N15/113C12N15/1137C12Y304/21021C12N2310/14C12N2310/315C12N2310/322C12N2310/3231C12N2310/346C12N2310/351C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,657,294
App. No.
14/861,805
Granted
May 23, 2017
Kind
B2
Abstract

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.

Claims (36)

1. A compound comprising:

(I) a short interfering nucleic acid (siNA) molecule capable of inhibiting expression of a human coagulation factor VII gene, said siNA molecule consisting of a single-stranded polynucleotide comprising a nucleotide sequence complementary to a Factor VII RNA, wherein said single-stranded polynucleotide:

i) is about 18 to 20 nucleotides in length;

ii) comprises 10 or more phosphorothioate internucleotide linkages;

iii) comprises 10 or more modified pyrimidines chosen from 2′ deoxy pyrimidine, 2′-O-methyl pyrimidine, 2′-deoxy-2′-fluoro pyrimidine, locked nucleic acid (LNA) pyrimidine, 2′-methoxyethoxy (MOE) pyrimidine, or a combination thereof; and

(II) a galactosamine.

2. The compound of claim 1 , wherein the single-stranded polynucleotide comprises 10 or more 2′-deoxy nucleotides.

3. The compound of claim 1 , wherein the single-stranded polynucleotide comprises one or more 2′-methoxyethoxy (MOE) nucleotides.

4. The compound of claim 1 , wherein the single-stranded polynucleotide comprises 1, 2, 3, 4, 5 or more locked nucleic acid (LNA) nucleotides, which is/are located at the 5′-end, the 3′-end, or both of the 5′ and 3′-ends, of the single-stranded polynucleotide.

5. The compound of claim 1 , wherein the single-stranded polynucleotide comprises 10 or more 2′ deoxy pyrimidines, 2′-O-methyl pyrimidines, or 2′-deoxy-2′-fluoro pyrimidines.

6. The compound of claim 1 , wherein the galactosamine comprises N-acetylgalactosamine which is a mono-antennary galactosamine, bi-antennary galactosamine or a tri-antennary galactosamine.

7. The compound of claim 1 , wherein the galactosamine is attached at the 5′-end or the 3′-end of the single-stranded polynucleotide.

8. A conjugate comprising:

(I) a short interfering nucleic acid (siNA) molecule capable of inhibiting expression of a human coagulation factor VII gene, said siNA molecule consisting of a single-stranded polynucleotide comprising a nucleotide sequence complementary to a human Factor VII RNA, wherein said single-stranded polynucleotide:

i) is about 18 to 20 nucleotides in length;

ii) comprises 10 or more phosphorothioate internucleotide linkages;

iii) comprises 10 or more modified pyrimidines chosen from 2′ deoxy pyrimidine, 2′-O-methyl pyrimidine, 2′-deoxy-2′-fluoro pyrimidine, locked nucleic acid (LNA) pyrimidine, 2′-methoxyethoxy (MOE) pyrimidine, or a combination thereof; and

(II) a galactosamine attached at the 5′-end or the 3′-end of the single-stranded polynucleotide.

9. The conjugate of claim 8 , wherein the single-stranded polynucleotide comprises 10 or more 2′-deoxy nucleotides.

10. The conjugate of claim 9 , wherein the single-stranded polynucleotide comprises one or more 2′-methoxyethoxy (MOE) nucleotides.

11. The conjugate of claim 9 , which comprises 1, 2, 3, 4, 5 or more locked nucleic acid molecules located at the 5′-end, the 3′-end, or both of the 5′ and 3′-ends, of the single-stranded polynucleotide.

12. The conjugate of claim 8 , wherein the single-stranded polynucleotide comprises 5 or more 2′ deoxy pyrimidines.

13. The conjugate of claim 12 , wherein the galactosamine is a mono-antennary galactosamine, bi-antennary galactosamine or a tri-antennary galactosamine.

14. A short interfering nucleic acid (siNA) molecule capable of inhibiting expression of a human coagulation factor VII gene, said siNA molecule consisting of a single-stranded polynucleotide comprising a nucleotide sequence complementary to a human Factor VII RNA, wherein said single-stranded polynucleotide:

i) is 20 nucleotides in length;

ii) comprises 10 or more phosphorothioate internucleotide linkages; and

iii) comprises 10 or more modified pyrimidines chosen from 2′ deoxy pyrimidine, 2′-O-methyl pyrimidine, 2′-deoxy-2′-fluoro pyrimidine, 2′-methoxyethoxy (MOE) pyrimidine or a combination thereof.

15. The siNA molecule of claim 14 , wherein the single-stranded polynucleotide further comprises a ligand chosen from a galactosamine or a cholesterol.

16. The siNA molecule of claim 14 , wherein the single-stranded polynucleotide comprises one or more 2′-methoxyethoxy (MOE) nucleotides.

17. The siNA molecule of claim 14 , wherein the single-stranded polynucleotide comprises 1, 2, 3, 4, 5 or more locked nucleic acid (LNA) nucleotides, wherein said LNA nucleotides is/are located at the 5′-end, the 3′-end, both of the 5′ and 3′-ends, of the single-stranded polynucleotide.

18. The conjugate of claim 8 , wherein the single-stranded polynucleotide comprises 10 or more modified pyrimidines chosen from 2′ deoxy pyrimidines, 2′-O-methyl pyrimidines, or 2′-deoxy-2′-fluoro pyrimidines.

19. The conjugate of claim 8 , wherein the single-stranded polynucleotide comprises 1, 2, 3, 4, 5 or more locked nucleic acid (LNA) nucleotides, wherein said LNA nucleotides is/are located at the 5′-end, the 3′-end, both of the 5′ and 3′-ends, of the single-stranded polynucleotide.

20. The compound of claim 1 , wherein the single-stranded polynucleotide comprises 5 or more 2′ deoxy pyrimidines.

21. The siNA molecule of claim 14 , wherein the single-stranded polynucleotide comprises 5 or more 2′ deoxy pyrimidines.

22. The compound of claim 1 , wherein the single-stranded polynucleotide is 20 nucleotides long.

23. The conjugate of claim 8 , wherein the single-stranded polynucleotide is 20 nucleotides long.

Assignments (1)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
Continuity (18)
Continuation In Part 14514112 · Oct 14, 2014
Continuation 14083525 · Nov 19, 2013
Continuation 13480655 · May 25, 2012
Continuation 10720448 · Nov 24, 2003
Continuation In Part 10693059 · Oct 23, 2003
Continuation In Part 10444853 · May 23, 2003
Continuation In Part 10652791 · Aug 29, 2003
Continuation In Part PCTUS0305346 · Feb 20, 2003
Continuation In Part PCTUS0305028 · Feb 20, 2003
Continuation In Part 10427160 · Apr 30, 2003
Provisional Application 60440129 · Jan 15, 2003
Provisional Application 60409293 · Sep 9, 2002
Provisional Application 60408378 · Sep 5, 2002
Provisional Application 60406784 · Aug 29, 2002
Provisional Application 60386782 · Jun 6, 2002
Provisional Application 60363124 · Mar 11, 2002
Provisional Application 60358580 · Feb 20, 2002
Related Publication 20160053269A1 · Feb 25, 2016